2025 will be remembered as the year psychedelic medicine crossed from science story to investable pharmaceutical category. The fourth quarter alone brought a corporate reshaping of the sector's flagship names: atai completed its combination with Beckley Psytech, redomiciled to the United States, and joined the Nasdaq Biotechnology Index, while Cybin announced its transformation into Helus Pharma with a move to Nasdaq. Underneath the branding, the fundamentals hardened — positive extension data, a resolved regulatory overhang at GH Research setting up for early 2026, and a widening base of state and federal access programs.
This year-end analysis reviews the developments that closed out 2025 and frames the catalysts that will define 2026.
Index Performance
The Psychedelic Invest Index (GPI) declined -4.2% across the fourth quarter of 2025, moving from 186.6 on 2025-09-30 to 178.7 on 2025-12-31. It ranged from an intraperiod low of 178.7 (2025-12-31) to a high of 191.0 (2025-12-23). Track the live index and its constituents on our Stock Index page.
Clinical & Pipeline Milestones
The engine of the sector remains its clinical readouts. Here are the trial results, regulatory designations, and pipeline milestones that moved the needle this period.
Reunion Neuroscience Inc. (Private). Reunion Neuroscience dosed the first patient in REKINDLE, a Phase 2 trial evaluating its serotonergic candidate RE104 for adjustment disorder in patients with cancer and other serious medical illnesses. Topline results are anticipated in 2027. The start follows the company's upsized $133 million Series A closing earlier in September.
Numinus Wellness Inc. (NUMIF). Numinus Wellness disclosed that Davidson & Company resigned as its independent auditor and MNP was engaged to complete the audit for the fiscal year ended August 31, 2025. The change came while the company remained subject to a cease-trade order and worked with the British Columbia Securities Commission to resolve disclosure questions. The governance turbulence added uncertainty for shareholders of the psychedelic services provider.
atai Life Sciences / Beckley Psytech (ATAI). The FDA awarded Breakthrough Therapy designation to BPL-003, Beckley Psytech's intranasal mebufotenin (5-MeO-DMT) benzoate, for treatment-resistant depression. The designation grants expedited development and closer FDA guidance, following positive Phase 2b data reported in July. It reinforced BPL-003 as a lead asset heading into the atai-Beckley combination.
Silo Pharma, Inc. (SILO). Silo Pharma provided a corporate update on its lead candidate SPC-15, an intranasal treatment for PTSD and anxiety, saying it is preparing an IND application to the FDA after positive safety study results and continued work on its delivery system. Separately, the company launched a digital-asset treasury strategy, disclosing initial cryptocurrency purchases. The dual announcement mixed clinical progress with an unconventional balance-sheet move.
Delix Therapeutics (Private). Delix Therapeutics announced interim Phase 1b efficacy data for DLX-001 (zalsupindole), an orally bioavailable 5-MeO-DMT analog engineered to promote neuroplasticity without hallucinogenic effects. Patients showed roughly a 12-point MADRS decrease (about 50%) by day 8, sustained through day 36, with mild, non-serious adverse events. The FDA also cleared a Phase 2 trial design allowing at-home self-administration, a notable regulatory step for the non-hallucinogenic approach.
Bright Minds Biosciences Inc. (DRUG). Bright Minds Biosciences said management would present at investor and scientific conferences, highlighting its selective 5-HT2 agonist portfolio led by BMB-101 for drug-resistant epilepsy and other CNS disorders. The update accompanied the company's broader plans to advance BMB-101 following positive Phase 2 data. It kept the epilepsy-focused developer in front of investors during a busy financing stretch for the sector.
Compass Pathways plc (CMPS). In its third-quarter 2025 results, Compass Pathways said a positive Type B meeting with the FDA supports a rolling NDA submission for COMP360 psilocybin in treatment-resistant depression and that it now expects a potential approval decision in late 2026 or early 2027, roughly 9 to 12 months earlier than previously guided. The company detailed plans to accelerate commercial launch preparations. Shares reacted sharply to the improved regulatory timeline.
atai Life Sciences / Beckley Psytech (ATAI). atai Life Sciences and Beckley Psytech completed their strategic combination to create AtaiBeckley, following shareholder approval at a November 4 extraordinary general meeting where roughly 98% of votes cast favored the deal. Shareholders also approved redomiciliation to Delaware. The merger consolidates BPL-003 (mebufotenin) and atai's broader pipeline under one company positioned as a leading psychedelic mental-health developer.
AtaiBeckley Inc. (ATAI). AtaiBeckley reported that a second, 12 mg dose of its intranasal mebufotenin (5-MeO-DMT) candidate BPL-003, given roughly eight weeks after an initial dose, was well tolerated and produced additional rapid, durable antidepressant effects. Pooled active-core patients (n=60) showed a mean MADRS reduction of 19.0 points with a 63% response and 48% remission rate at Day 57. The company said the data support a two-dose regimen heading into a planned Phase 3 program, with an FDA End-of-Phase 2 meeting scheduled and Phase 3 guidance expected in Q1 2026.
Cybin Inc. (CYBN). Cybin delivered its quarterly financial results and business update, reiterating that its Phase 2 CYB004 study in generalized anxiety disorder had completed enrollment with topline data expected in Q1 2026, and that dosing continued in the Phase 3 APPROACH study of CYB003 in major depressive disorder. The update underscored the company's late-stage pipeline positioning as it advanced its multinational Phase 3 PARADIGM program for adjunctive MDD treatment.
MindBio Therapeutics Corp. (MBIO). MindBio Therapeutics shared results from its 89-patient Phase 2b trial of repeated take-home microdosed LSD (MB22001) in major depressive disorder, which failed to demonstrate superiority over placebo. The disappointing readout — described by industry observers as the collapse of the largest LSD microdosing program to date — raised fresh questions about the therapeutic value of microdosing relative to full-dose psychedelic approaches being pursued by peers.
Bright Minds Biosciences Inc. (DRUG). Bright Minds Biosciences announced four additions to its scientific advisory board to support clinical development of its selective 5-HT2C agonist BMB-101 and newly nominated candidate BMB-105, including its recently launched Prader-Willi syndrome (PWS) program. The move followed the company's early-November initiation of a Phase 2a NOVA study and positioned it ahead of key epilepsy and neurodevelopmental data readouts anticipated in early 2026.
Mind Medicine (MindMed) Inc. (MNMD). MindMed management presented at the Jefferies Global Healthcare Conference in London, part of a run of investor appearances (Stifel, Jefferies, Evercore and Piper Sandler) through November and December. The company reiterated that its pivotal Phase 3 trials of MM120 (lysergide) in generalized anxiety disorder and major depressive disorder remained on track, with topline readouts expected across 2026 and roughly $209 million in cash following an October raise.
NRx Pharmaceuticals, Inc. (NRXP). NRx Pharmaceuticals said the FDA received and deemed substantially complete its Abbreviated New Drug Application for KETAFREE, a single-patient, preservative-free IV ketamine formulation, assigning a July 29, 2026 review goal date. KETAFREE is positioned as an alternative to multidose ketamine vials containing benzethonium chloride, and the filing advances NRx's broader ketamine franchise, which also includes NRX-100 for suicidal depression.
PharmAla Biotech Holdings Inc. (MDMA). PharmAla Biotech announced it completed release testing on its first batch of LaNeo MDMA 40 mg capsules manufactured in Australia, a step toward localizing supply for the country's Authorised Prescriber scheme. Domestic Australian production could shorten supply chains and strengthen PharmAla's position as a commercial MDMA supplier in the world's only market that regulates MDMA as a prescribable medicine.
Policy, Regulation & Access
Psychedelic policy accelerated on multiple fronts — federal, state, and international. These developments shape the demand-side runway for every developer we track.
U.S. Congress (Freedom to Heal Act). Senators Cory Booker and Rand Paul, with House companions Madeleine Dean and Nancy Mace, introduced the Freedom to Heal Act, which would create a DEA-regulated physician registration process allowing patients with severe, life-threatening conditions to access Schedule I 'eligible investigational drugs' such as MDMA and psilocybin under the federal Right to Try framework. To qualify, a drug must have completed Phase 1 trials. The bill signals continued federal momentum on psychedelic access for veterans and terminally ill patients.
New Mexico Department of Health. New Mexico's newly formed seven-member Medical Psilocybin Advisory Board held its first public meeting, where state health officials revealed plans to launch the medical psilocybin program by the end of December 2026 — roughly a year ahead of the legislative deadline. The board is tasked with setting clinical standards, training, licensing and care-delivery rules for qualifying conditions including treatment-resistant depression, PTSD, substance use disorders and end-of-life care.
UTHealth Houston / UTMB Health (State of Texas). UTHealth Houston and UTMB Health were awarded $50 million from the Texas Health and Human Services Commission to lead the IMPACT consortium, a two-year multicenter trial evaluating ibogaine for addiction, traumatic brain injury and other behavioral-health conditions. Authorized under Senate Bill 2308 and joined by a broad group of Texas universities and hospitals, it represents the largest publicly funded psychedelic research initiative to date and aims to pursue FDA-approved trials with drug-developer and hospital partners.
Czech Republic (Ministry of Health). The Czech Republic confirmed the clinical conditions for its medical psilocybin framework, with a government decree setting out that certified psychiatrists with psychedelic training may administer synthetic psilocybin to patients with cancer-related depression, serious non-psychotic depression, or life-threatening deteriorations in mental state. Rollout will initially be limited to a few dozen patients annually, mainly in Prague and Brno, making Czechia the first EU member state with a full legal framework for medical psilocybin.
Capital Markets, M&A & Corporate
Financings, listings, and dealmaking tell you where conviction is flowing. This is how the sector's balance sheets and corporate structures shifted.
atai Life Sciences N.V. (ATAI). atai priced an underwritten offering of common shares at $5.48 each, drawing new institutional investors including Janus Henderson, Foresite Capital, Deep Track Capital and HBM Partners alongside existing backers. With the underwriters' option exercised, the deal totaled about 27.3 million shares for approximately $149.5 million in gross proceeds. The capital bolsters atai's balance sheet ahead of its Beckley Psytech merger and Phase 3 plans.
Cybin Inc. (CYBN). Cybin unveiled a registered direct offering of about 22.28 million common shares and pre-funded warrants priced at $6.51, for aggregate gross proceeds of roughly $175 million. The company said it would use proceeds to repay outstanding convertible debentures held by High Trail Special Situations and to advance its CYB003, CYB004 and CYB005 programs. The raise materially strengthened Cybin's cash runway for its Phase 3 depression work.
Cybin Inc. (CYBN). Cybin completed its previously announced registered direct offering, confirming the roughly $175 million raise closed on October 31. The proceeds retire the company's High Trail convertible debentures and fund continued clinical development. The completed financing removed a debt overhang and extended Cybin's runway into its pivotal trial readouts.
GH Research PLC (GHRS). GH Research reported third-quarter 2025 results, ending the period with $293.9 million in cash and marketable securities. The company highlighted its Phase 2b program for inhalable 5-MeO-DMT (GH001) in treatment-resistant depression, including an open-label extension showing a 73% remission rate at six months, and reaffirmed plans to start a global pivotal program in 2026. It also continued working with the FDA to resolve the remaining topic on its U.S. IND clinical hold.
Mind Medicine (MindMed) Inc. (MNMD). MindMed reported third-quarter 2025 results, with R&D expense of about $31.0 million driven by its MM120 (LSD) program. Management said enrollment across its three pivotal MM120 orally disintegrating tablet trials for anxiety and depression remained on track, with Voyage topline data expected in the first half of 2026 and additional Phase 3 readouts later in 2026. CEO Rob Barrow characterized 2025 as a year of strong execution.
Optimi Health Corp. (OPTH). Optimi Health said it will supply GMP 40 mg and 60 mg MDMA capsules for MAPS Israel's 'Healing October 7th' clinical program, an open-label, multicenter PTSD study approved by the Israeli Ministry of Health. The 168-participant trial, sponsored by Sheba Medical Center, compares individual versus group MDMA-assisted therapy, and Optimi confirmed it had already completed its first export shipment to Israel — extending its international commercial supply footprint beyond Australia.
Numinus Wellness Inc. (NUMI). Numinus Wellness issued a corporate update disclosing that the Toronto Stock Exchange began a delisting review in November 2025, that it is under a cease trade order it is working to revoke with the BCSC, and that it cycled through multiple auditors in October. Having sold its U.S. wellness clinics and wound down non-core subsidiaries, the company said it is now focused on two segments: its clinical trial site network and practitioner training platform.
AtaiBeckley Inc. (ATAI). The USPTO granted AtaiBeckley a new patent covering the drug substance of EMP-01, an oral (R)-MDMA formulation being developed for social anxiety disorder, providing expected exclusivity through 2043. The patent claims a highly crystalline, thermodynamically stable HCl salt form with high aqueous solubility. EMP-01 is in exploratory Phase 2a, with topline data expected in the first quarter of 2026.
Cybin Inc. (CYBN). Cybin announced it would voluntarily transfer its U.S. listing from NYSE American to the Nasdaq Global Market and do business as Helus Pharma, trading under the new ticker HELP instead of CYBN. The company said its shares would stop trading on NYSE American at the close on January 2, 2026 and begin on Nasdaq on January 5, framing the move as aligning the late-stage developer with a larger biopharma peer group to boost investor visibility.
AtaiBeckley Inc. (ATAI). AtaiBeckley announced its common stock was added to the Nasdaq Biotechnology Index (NBI), effective before the market open on December 22, 2025. The index inclusion — a milestone that typically broadens passive-fund ownership — capped a year in which the company raised roughly $300 million, completed the atai–Beckley Psytech combination, and advanced BPL-003, VLS-01 and EMP-01 in Phase 2 development.
PharmAla Biotech Holdings Inc. (MDMA). PharmAla Biotech filed a registration statement with the U.S. Securities and Exchange Commission detailing a securities offering, part of a series of capital-markets moves that included an earlier base shelf prospectus and a Radium Capital loan facility against Australian R&D tax incentives. The filings aim to give the MDMA supplier financing flexibility as it scales commercial production.
Cybin Inc. (CYBN). Cybin initiated an at-the-market equity program allowing it to sell up to US$100 million of common shares from treasury at prevailing prices, managed by Cantor Fitzgerald and established via a prospectus supplement dated December 30, 2025. The program gives the company flexible access to capital to fund its late-stage CYB003 and CYB004 programs just ahead of its Nasdaq listing transition and Helus Pharma rebrand; some coverage noted the stock dipped on the dilution potential.
AtaiBeckley Inc. (ATAI). AtaiBeckley completed its corporate redomiciliation to the United States following the close of Nasdaq trading on December 30, 2025, exchanging all outstanding Atai Beckley N.V. ordinary shares one-for-one for shares of Delaware-incorporated AtaiBeckley Inc. Approved by roughly 99% of votes at the company's November EGM, the shares continue trading on Nasdaq under 'ATAI,' with headquarters in New York, simplifying the corporate structure for U.S. investors.
What to Watch
The 2026 setup is unusually catalyst-rich. Compass Pathways carries two positive Phase 3 psilocybin readouts toward a rolling NDA; MindMed (soon Definium) has three Phase 3 lysergide readouts queued across depression and anxiety; GH Research enters the year with its clinical hold lifted; and AtaiBeckley advances BPL-003 toward pivotal trials. Layer on the state-level access wave — Texas's $50 million ibogaine program, New Mexico, New Jersey, and a Czech medical-psilocybin framework — and 2026 shapes up as the year clinical validation and market access arrive together.
This report is compiled by Psychedelic Invest from primary company disclosures and industry reporting; each story links its source. It is provided for informational purposes only and is not investment advice.